Boston Therapeutics Strengthens its Medical Advisory Board

1 Minute Read

Boston_Logo_300_dpi_smallBoston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director and a member of its Medical Advisory Team. Dr. Tan is expected to help guide the Company's development of its diabetes-related treatments.

Dr. Tan is a professor of internal medicine at the University of Michigan and attending physician in metabolism, endocrinology, and diabetes at the University of Michigan Health System. A member of the American Diabetes Association and the American College of Endocrinology, he is the author or coauthor of more than 110 peer-reviewed publications in the area of diabetes and carbohydrate metabolism. He is a past senior medical director of the Diabetes Endocrine Platform Team at Eli Lilly. He received an M.D. from Dalhousie University.

Visit our Corporate Profile and Key Points pages for more
information, including the latest research and headlines,
on Boston Therapeutics, Inc. (BTHE-OTCQB).